HGEN News and Press, Humanigen Inc. From 06/08/22

Rigel Pharmaceuticals (RIGL) -49% after reports top-line results from FORWARD Phase 3 trial of Fostamatinib in patients with warm autoimmune hemolytic anemia. AeroClean Technologies (AERC) -17%. The Scotts Miracle-Gro SMG -13% as it cuts revenue and EPS outlook for FY2022....

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that representatives will present and participate at multiple inv...

The following slide deck was published by Humanigen, Inc. in conjunction with this event. For further details see: Humanigen (HGEN) Presents At H.C. Wainwright Global Investment Conference - Slideshow

One in five COVID-19 survivors aged 18 – 64 years in the U.S. may have developed at least one condition linked to long COVID, a large new study conducted by the Centers for Disease Control and Prevention (CDC) indicates. The prevalence is even higher among those aged 65 years and older...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced that Cameron Durrant, Chairman & CEO, will give a corporate present...

GeoVax Labs (GOVX) +20%. Inovio Pharmaceuticals (INO) +19%. SIGA Technologies SIGA +15% Monkeypox plays indicate further upside as global toll climbs. O2Micro International (OIIM) +13%. GoldMining (GLDG) +12%. Emergent BioSolutions EBS +12% Monkeypox plays indicate further...

Humanigen press release (NASDAQ:HGEN): Q1 GAAP EPS of -$0.32 beats by $0.14. Revenue of $1.04M (+112.2% Y/Y) beats by $0.83M. Shares +1.09% AH. For further details see: Humanigen GAAP EPS of -$0.32 beats by $0.14, revenue of $1.04M beats by $0.83M

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate, lenzilumab (LENZ ® ), today provided a corporat...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that management will present and participate at multiple investors con...

In a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to standard of care (SOC) could result in over £5.5 million in cost savings weekly 1 Lenzilumab plus SOC resulted in per‑patient cost savings between £8,462 and £17,277 (net s...